Novo Nordisk has spent the last two years scrambling to keep up with skyrocketing demand for its blockbuster GLP-1 drugs, the obesity-focused Wegovy and Type 2 diabetes med Ozempic, forcing it to outsource some production of both the drug and its accompanying syringes and injection devices. As it continues to build out its GLP-1 portfolio, the Danish drugmaker has recruited yet another helping hand.
Joining the assembly line is Ypsomed, which has signed on to manufacture “large quantities of autoinjectors” for Novo, it announced Wednesday.
Ypsomed said in the release that the autoinjectors will be used to deliver 1-milliliter doses of various drugs for metabolic conditions, including new medications currently undergoing clinical trials; the Swiss devicemaker’s head of investor relations, Thomas Kutt, told Reuters that the autoinjectors will specifically be paired with Novo’s “second-generation GLP-1s.”
